CAP-T™ Cells
CAP-T™ cells operate through a unique intracellular signaling mechanism that bypasses the TCR regulatory pathways. This design overcomes challenges posed by traditional therapies. Additionally, it enables the use of small molecules to regulate CAP-T™ cell activities, providing accurate and adjustable therapeutic options.
CAP-T cells circumvent TCR limitations, enabling precise and adaptable tumor targeting
The Power of CAP-T™
-
Bypasses TCR Activation
CAP doesn't require T-cell receptor (TCR) activation, which often encounters regulatory and inhibitory mechanisms that restrict its full potential.
-
Enhanced Potency and Sensitivity
Avoiding the regulatory mechanisms associated with TCR activation is anticipated to amplify T-cell signaling and immunotherapy sensitivity.
-
Resistance to Exhaustion
T-cells equipped with recombinant molecules are projected to be more resilient against exhaustion triggered by molecules targeting TCR activation.
TCR
CAR
CAP-T™
CAP-T™ beats CAR
Chimeric Adapter Proteins (CAPs) can bypass upstream proteins and signal to downstream proteins.
Schematic of TCR signaling, CAR signaling, and CAP signaling. While TCR and CAR must cross the signaling threshold (indicated as yellow highlighted bar) for productive T cell activation, CAP bypasses upstream steps.
